Form 4: CRISPR Therapeutics Director Receives Stock Option Grant

Director Maria Fardis was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard equity compensation.

Summary

• Director Maria Fardis received a grant of 13,000 stock options on June 5, 2026.
• The options have an exercise price of $51.84 per share.
• The options are set to expire on June 5, 2036.
• Vesting occurs in 12 equal monthly installments starting June 30, 2026, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is subject to market volatility and the future performance of CRSP common shares.

Future Outlook

The options vest over a one-year period, incentivizing the director's continued service through the 2027 Annual Meeting.

Management Comments

• The grant is subject to continued service to the Company or any of its subsidiaries.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain high-level scientific and executive expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotech firms.
• The one-year vesting period is relatively aggressive compared to the multi-year vesting schedules often seen in broader industry benchmarks.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first installment on June 30, 2026.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Director Compensation, Stock Options, Insider Transaction, Biotech